0L35 Stock Chart & Stats
$16.42
-$1.09(-6.61%)
At close: 4:00 PM EDT
$16.42
-$1.09(-6.61%)
Day’s Range― - ―
52-Week Range$14.35 - $25.34
Previous CloseN/A
Volume6.86K
Average Volume (3M)8.71K
Market Cap
$2.00B
Enterprise Value$2.15K
Total Cash (Recent Filing)$788.49M
Total Debt (Recent Filing)$1.05B
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Nov 04, 2026EPS Estimate
0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding105,627,020
10 Day Avg. Volume5,874
30 Day Avg. Volume8,708
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.98
Price to Sales (P/S)1.03
P/FCF Ratio-7.33
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$22.87Price Target Upside39.26% Upside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)3.24
Revenue Forecast (FY)$1.84B
Bulls Say, Bears Say
Bulls Say
Stable PMO Franchise With Strong Gross MarginsThe established PMO franchise provides a recurring commercial base supported by high patient adherence and strong gross margins. This foundation can help Sarepta fund pipeline investment and cushion volatility in newer gene-therapy products.
Operating Discipline And Improved LiquidityMaintained operating profitability alongside substantial expense reductions shows management is adapting its cost base to changing revenue conditions. Higher cash and investments also improve flexibility to support clinical programs and commercial execution.
Broadening Pipeline And Collaboration RevenueRegulatory progress for additional exon-skipping indications and advancing siRNA programs broaden Sarepta’s potential beyond its current products. The Roche-related collaboration stream further diversifies revenue and can support future development.
Bears Say
Declining Revenue And Near-term ELEVIDYS PressureThe sharp revenue decline and expected H2 softness indicate that growth has not yet stabilized, particularly for ELEVIDYS. A prolonged conversion lag and weaker demand could pressure operating leverage and make earnings dependent on collaboration receipts.
Persistent Negative Operating And Free Cash FlowDespite recent cash improvement and reported operating income, historical and TTM cash flows show that Sarepta has not demonstrated durable self-funding operations. Continued clinical, manufacturing, and commercial spending may require substantial liquidity.
Regulatory, Safety, And Competitive ConstraintsClinical holds and delayed safety data restrict the timing of pipeline expansion and nonambulatory label opportunities. At the same time, potential exon-skipping competition could weaken PMO growth, adoption, or commercial durability over time.
Sarepta Therapeutics News
0L35 FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest share price was $14.35 and its highest was $25.34 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $2.00B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Nov 04, 2026 which is in 68 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Aug 05, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of $0.217 by -$0.267.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Sarepta Therapeutics dividends here
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is 0.17.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 105,627,020 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of -$0.05 in its last earnings report, missing expectations of $0.217. Following the earnings report the stock price went up 2.141%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in GB:0L35
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sarepta Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$22.87 (39.26% Upside)
$22.87 (39.26% Upside)
Blogger Sentiment
Bullish
GB:0L35 Sentiment 72%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.35%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
0L35 Company Deck
0L35 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: Sarepta demonstrated strong operational discipline (GAAP and non-GAAP profitability), meaningful cash growth, expense reductions, and progress across its siRNA and regulatory programs — all positive signs. However, a substantial year-over-year revenue decline (34% in Q2) driven by lower ELEVIDYS demand, near-term expectations for modestly lower product revenue in H2, a $39M litigation charge, and timing delays for key safety readouts temper the outlook. Pipeline catalysts and accepted sNDAs provide upside potential, but near-term top-line pressure and regulatory/timing uncertainties leave the narrative mixed.View all GB:0L35 earnings summaries0L35 Stock 12 Month Forecast
Average Price Target
$22.87
▲(39.26% Upside)
Technical Analysis
BioCryst
―
Mesoblast
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Dyne Therapeutics
―